A proof of principal study into a new vaccine to help combat cervical cancer has had a 100% success ...
A proof of principal study into a new vaccine to help combat cervical cancer has had a 100% success rate.
The results of the four-year trial, carried out by pharmaceutical manufacturer Merck, Sharp and Dohme, are due to be published by The New England Journal of Medicines.
The aim of the study was to help boost the immune system against human papilloma virus (HPV), the cause of most cases of cervical cancer. Of the 2,000 women given the vaccine, not one developed HPV. In contrast, 3.8% of those not immunised developed HPV.
The final stage of testing is currently underway and will involve around 250 women in the UK and 6,000 worldwide. The programme will take several years to complete.
